|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2,976.50 INR | +0.98% |
|
+1.63% | +7.50% |
| 06/05 | Nirmal Bang Downgrades Ajanta Pharma to Hold from Buy; Price Target is INR3,196 | MT |
| 06/05 | Ajanta Pharma Limited, Q4 2026 Earnings Call, May 05, 2026 |
| Capitalization | 37TCr 390.09Cr 337.82Cr 309.97Cr 291.63Cr 543.17Cr 551.66Cr 3.68TCr 1.43TCr 18TCr 1.46TCr 1.43TCr 63TCr | P/E ratio 2026 |
33.2x | P/E ratio 2027 * | 30.3x |
|---|---|---|---|---|---|
| Enterprise value | 36TCr 380.91Cr 329.87Cr 302.68Cr 284.77Cr 530.39Cr 538.68Cr 3.6TCr 1.4TCr 18TCr 1.43TCr 1.4TCr 61TCr | EV / Sales 2026 |
6.34x | EV / Sales 2027 * | 5.79x |
| Free-Float |
33.61% | Yield 2026 * |
1.11% | Yield 2027 * | 1.34% |
Last Transcript: Ajanta Pharma Limited
| 1 day | +0.98% | ||
| 1 week | +1.63% | ||
| Current month | +1.63% | ||
| 1 month | -3.87% | ||
| 3 months | -0.52% | ||
| 6 months | +12.72% | ||
| Current year | +7.50% |
| 1 week | 2,851.5 |  | 3,028.9 |
| 1 month | 2,850 | | 3,314.9 |
| Current year | 2,654.5 | | 3,314.9 |
| 1 year | 2,329.9 | | 3,314.9 |
| 3 years | 1,380 | | 3,485 |
| 5 years | 1,061.77 | | 3,485 |
| 10 years | 550 | | 3,485 |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 50 | - | |
| Chief Executive Officer | 54 | 21/12/2009 | |
| Director of Finance/CFO | 61 | 23/04/1998 |
| Director | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 54 | 01/01/1996 | |
| Chairman | 79 | 31/12/1979 | |
| Director/Board Member | 71 | 21/12/2009 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | |
|---|---|---|---|---|---|---|
| 28/25/28 | Sell | 548 | 0.0004% | |||
| 31/24/31 | Sell | 100 | 0.0001% | |||
| 31/24/31 | Sell | 100 | 0.0001% |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.98% | +1.63% | +15.76% | +110.96% | 390.09Cr | |
| +0.12% | -0.94% | +6.13% | +75.79% | 4.49TCr | |
| -1.81% | -9.69% | +56.09% | +96.84% | 3.48TCr | |
| +0.19% | +0.02% | -6.84% | +44.16% | 1.19TCr | |
| +0.41% | +1.05% | +13.42% | +111.27% | 1.15TCr | |
| 0.00% | +0.39% | +36.36% | +123.68% | 892.47Cr | |
| +0.34% | -7.17% | +16.86% | +35.69% | 705.16Cr | |
| +1.34% | -7.00% | +48.19% | -20.11% | 652.39Cr | |
| -0.66% | -4.78% | +36.22% | +243.02% | 641.49Cr | |
| +0.59% | -3.41% | -31.36% | -6.22% | 531.23Cr | |
| Average | +0.15% | -2.85% | +19.08% | +81.51% | 1.41TCr | |
| Weighted average by Cap. | -0.26% | -3.51% | +22.55% | +83.28% |
| 2026 | 2027 * | |
|---|---|---|
| Net sales | 5.35TCr 56Cr 49Cr 45Cr 42Cr 78Cr 79Cr 530.74Cr 206.56Cr 2.59TCr 210.99Cr 206.4Cr 9.01TCr | 6.27TCr 66Cr 57Cr 52Cr 49Cr 92Cr 93Cr 621.17Cr 241.75Cr 3.03TCr 246.94Cr 241.57Cr 11TCr |
| Net income | 1.05TCr 11Cr 9.52Cr 8.74Cr 8.22Cr 15Cr 16Cr 103.88Cr 40Cr 506.86Cr 41Cr 40Cr 1.76TCr | 1.23TCr 13Cr 11Cr 10Cr 9.62Cr 18Cr 18Cr 121.54Cr 47Cr 593.02Cr 48Cr 47Cr 2.06TCr |
| Net Debt | -874.5Cr -9.18Cr -7.95Cr -7.29Cr -6.86Cr -13Cr -13Cr -87Cr -34Cr -422.92Cr -34Cr -34Cr -1.47TCr | -881.7Cr -9.25Cr -8.01Cr -7.35Cr -6.92Cr -13Cr -13Cr -87Cr -34Cr -426.4Cr -35Cr -34Cr -1.48TCr |
| Date | Price | Change | Volume |
|---|---|---|---|
| 05/26/05 | 2,976.50 ₹ | +0.98% | 1,08,169 |
| 04/26/04 | 2,947.70 ₹ | +0.63% | 67,356 |
| 03/26/03 | 2,929.20 ₹ | +0.58% | 1,88,221 |
| 02/26/02 | 2,912.20 ₹ | -0.64% | 78,363 |
| 01/26/01 | 2,931.00 ₹ | +0.07% | 2,23,280 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- AJANTPHARM Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition